Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 10/21 10:00:15 pm
61.2 USD   -1.16%
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in A..
10/20MERCK & CO., IN : quaterly earnings release
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
share via e-mail
06/22/2012 | 07:32pm CEST
   By Jon Kamp 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at jon.kamp@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recu..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Blad..
10/20 MERCK : New Findings from Merck & Company Describe Advances in Clinical Trials a..
10/20 MERCK : Findings on Pneumonia Reported by Researchers at Merck & Company (Ceftol..
10/20 NEW PEPTIDE HYDROLASES STUDY RESULTS : Improving Aqueous Solubility...
10/20 MERCK : Studies from Merck Research Labs in the Area of Thrombosis Reported (Dif..
10/20MERCK & CO., INC. : quaterly earnings release
10/19 MERCK : Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antivi..
10/18 MERCK : Country Club Trust Company N.a. Lowers stake in Merck & Co.
10/17 MERCK : Research Laboratories Facilities Designated as “Milestones in Micr..
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/22 FDA OKs Merck's bezlotoxumab to reduce recurrence of C. diff infection in cer..
10/21 HERE'S HOW LILLY AND MERCK ARE FARIN : Earnings Out Next Week
10/21 Why You (And Another Company) Should Buy Gilead - Dividend Sensei
10/21 Merck's Keytruda successful in late-stage bladder cancer study
10/20 The Drug Battle Coming To A Neighborhood Near You
Financials ($)
Sales 2016 39 696 M
EBIT 2016 13 597 M
Net income 2016 5 663 M
Debt 2016 5 348 M
Yield 2016 2,97%
P/E ratio 2016 30,00
P/E ratio 2017 19,78
EV / Sales 2016 4,40x
EV / Sales 2017 4,30x
Capitalization 169 231 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.87%169 231
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.36%198 298
PFIZER INC.-0.31%195 193
More Results